DYSIS Medical lands $25M investment to expand in U.S., U.K. and other markets

A stethoscope and paper money.
DySIS Medical landed a $25 million investment that will be used to expand its business in the U.S., U.K. and other markets. (Getty)

DYSIS Medical of Scotland, which focuses on developing tools for women’s health, landed a $25 million investment the company said will be used to expand its business in the U.S., U.K. and other markets as well as for R&D purposes.

The finance infusion came from venture fund Lundbeckfonden Ventures, a longtime investor in DYSIS.

DYSIS is the developer of the Ultra colposcope that is used to screen for cervical cancer. The company said it has recently reached several key milestones in the latest version of the device with the publication of updated guidance recommending the adoption of the device by the U.K.’s National Health Service. Also, the publication of U.S. clinical data that indicated the device detected the cervical disease in 40% more of the women (7,555 patients in 45 clinics) in the study than if it had not been used.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The Ultra is a noninvasive device that aids physicians in detecting and diagnosing precancerous lesions of the cervix. DYSIS was founded in 2002.

“We greatly value our partnership with Lundbeckfonden Ventures and are delighted by their recognition of our progress and their support as we continue our objective of saving lives by making DYSIS the new standard for colposcopy,” Alastair Atkinson, DYSIS chief executive, said in a statement.

If identified at the precancerous stage, cervical lesions can be treated before they develop into cancer. Globally, cervical cancer is responsible for about 250,000 deaths a year, the company said.


Suggested Articles

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.